FF-10832

Phase 2Small molecule

FFujifilm Pharmaceuticals U.S.A., Inc.

FF-10832 is one of 63 small molecule programs targeting Biliary Tract Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Biliary Tract CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Biliary Tract CancerPhase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Lenvima

Eisai

Preclinical

6 2

Gilotrif

Boehringer Ingelheim

Preclinical

12 3

Ofev

Boehringer Ingelheim

Preclinical

7 4

FF-10832

FFujifilm Pharmaceuticals U.S.A., Inc.

Phase 2

1 5

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 6

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 7

REGN2810

Regeneron

Preclinical

1 8

Immune Checkpoint Inhibitors

PPeking Union Medical College Hospital

Preclinical

2 9

EGFR-TKI

SShanghai Pulmonary Hospital, Shanghai, China

Preclinical

1 10

Neoadjuvant Immunotherapy

RRenJi Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Active, not recruiting

Non-Small Cell Lung Cancer

NCT05318573

Clinical

Trials by Indication[1]

Biliary Tract Cancer1 trial

A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer

Active, not recruiting·FFujifilm Pharmaceuticals U.S.A., Inc.·Phase 1·NCT03440450·90 enrolled

Non-Small Cell Lung Cancer1 trial

A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer

Active, not recruiting·FFujifilm Pharmaceuticals U.S.A., Inc.·Phase 2·NCT05318573·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for FF-10832. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FF-10832 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FF-10832. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fujifilm Pharmaceuticals U.S.A., Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFujifilm Pharmaceuticals U.S.A., Inc.

FF-10832

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Biliary Tract Cancer1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News